search
Back to results

Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)

Primary Purpose

Diabetic Macular Edema

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Experimental: Group 1
Experimental: Group 2
Experimental: Group 3
Placebo: Group 4
Sponsored by
Rezolute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetic Macular Edema focused on measuring Diabetic Macular Edema, Diabetic Retinopathy, Diabetes, Retinal, Macular Thickening, Plasma Kallikrein Inhibitor

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: General Inclusion Criteria: Confirmed diabetes mellitus Type 1 or Type 2 Stable glycemic control Study Eye Inclusion Criteria: Mild to moderate non-proliferative diabetic retinopathy (NPDR) with retinal thickening due to CI-DME as determined by the Investigator. Spectral Domain Optical Coherence Tomography (SD-OCT) foveal CST at screening measuring ≥320 µm (or corresponding values) Best Corrected Visual Acuity ETDRS letter score at 4 meters of ≤78 letters at screening. Media clarity, pupillary dilation, and participant cooperation sufficient for adequate clinical evaluations, OCT images and fundus photographs, at screening. Fellow Eye Inclusion Criteria: Best Corrected Visual Acuity ETDRS letter score at 4 meters of ≥5 letters at screening. Exclusion Criteria: Study Eye Exclusion Criteria: Received more than 3 anti-VEGF injections (including Avastin) and/or received a recent anti-VEGF injection within 8 weeks of Randomization. Any history of retinal surgery or other surgical intervention for DME. Intraocular surgery (including cataract surgery), within 12 weeks prior to Randomization, or anticipated need for ocular surgery during the study period. History of trabeculectomy or other filtration surgery (prior laser trabeculoplasty and placement of iStent®1 in conjunction with cataract surgery is permitted if the procedure took place ≥12 weeks prior to Randomization). Autoimmune idiopathic inflammatory eye disease such as anterior uveitis, or participants with history or signs of chronic inflammation. Full thickness macular hole or retinal detachment. Panretinal, macular focal, or grid laser photocoagulation within 16 weeks of Randomization or anticipated need for the use of laser photocoagulation during the study period. Uncontrolled glaucoma, at screening, defined as IOP ≥25 mmHg. The use of corticosteroids as follows: Topical corticosteroids within 12 weeks prior to Randomization and throughout the remainder of the study. Use of intraocular or sub-Tenon's steroids within 2 years of Randomization in phakic eyes or 9 months of Randomization in pseudophakic eyes, and throughout the remainder of the study. Fellow Eye Exclusion Criteria: Intraocular or sub-Tenon's steroid injection within 6 months of Randomization and throughout the remainder or the study. General Exclusion: Use of the following medications or substances within the specified timeframes below and throughout the remainder of the study. a. Within 16 weeks of Randomization: i. Systemic anti-VEGF or pro-VEGF treatments ii. Systemic, approved, or off-label drugs or devices used to treat DME iii. Participated in an investigational drug or device study within 16 weeks or 5 half-lives (whichever is longer) of Randomization, including systemic or ocular studies iv. Initiation of drugs or substances known to improve or worsen macular edema e.g., Latanoprost or phosphodiesterase-5 (PDE-5) inhibitors (e.g., Sildenafil or others in PDE-5 class), but participants may remain on these drugs if they were initiated >16 weeks prior to Randomization. b. Within 12 weeks of Randomization: i. Use of tobacco- or nicotine- containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, vaping). c. Within 4 weeks of Randomization: i. Anti-coagulants, except for aspirin ≤325 mg/day and/or clopidogrel ≤75 mg/day (or equivalent drug class) ii. Total daily doses of Metformin >1000 mg iii. Total daily doses of niacin (Vitamin B3) >1.5 g/day iv. Use of systemic steroids at supraphysiologic doses (e.g., prednisone equivalent of 5 mg/day or hydrocortisone equivalent of 20 mg/day). v. Drugs that may affect the retina or optic nerve such as quinolones, thioridazine, deferoxamine, ethambutol, vigabatrin, and pentosan. Alanine aminotransferase (ALT), or aspartate aminotransferase (AST), or alkaline phosphatase (ALP) ≥2X upper limit of normal (ULN), total bilirubin ≥1.5X ULN, or gamma-glutamyl transferase (GGT) ≥3X ULN as per the central laboratory. Estimated glomerular filtration rate (eGFR) at ≤45 mL/min and/or history of persistent micro or macro albuminuria. History of current or prior (within 1 year of Randomization) any significant illness, or any medical history History of bariatric surgery or other surgical or medical history History of current or prior (within 1 year of Randomization) abnormal, clinically significant ECG including inadequately controlled hypertension History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding. Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury Known history of human immune-deficiency virus (HIV), hepatitis C, or hepatitis B infection. Malignancies within 3 years prior to Randomization Donated more than 500 mL of blood or significant blood loss within 60 days before Randomization.

Sites / Locations

  • Rezolute Investigative Site, Phoenix, ArizonaRecruiting
  • Rezolute Investigative Site, Beverly Hills, CaliforniaRecruiting
  • Rezolute Investigative Site, Fullerton, CaliforniaRecruiting
  • Rezolute Investigative Site, Modesto, CaliforniaRecruiting
  • Rezolute Investigative Site, Santa Barbara, CaliforniaRecruiting
  • Rezolute Investigative Site, Coral Springs, FloridaRecruiting
  • Rezolute Investigative Site, Winter Haven, FloridaRecruiting
  • Rezolute Investigative Site, Augusta, GeorgiaRecruiting
  • Rezolute Investigative Site, Oak Forest, IllinoisRecruiting
  • Rezolute Investigative Site, Hagerstown, Maryland
  • Rezolute Investigative Site, Royal Oak, Michigan
  • Rezolute Investigative Site, Saint Louis Park, MinnesotaRecruiting
  • Rezolute Investigative Site, Saint Louis, MissouriRecruiting
  • Rezolute Investigative Site, Reno, Nevada
  • Rezolute Investigative Site, Bloomfield, New Jersey
  • Rezolute Investigative Site, Great Neck, New YorkRecruiting
  • Rezolute Investigative Site, New York, New York
  • Rezolute Investigative Site, Springfield, OregonRecruiting
  • Rezolute Investigative Site, Ladson, South CarolinaRecruiting
  • Rezolute Investigative Site, Austin, TXRecruiting
  • Rezolute Investigative Site, Bellaire, TexasRecruiting
  • Rezolute Investigative Site, McAllen, TexasRecruiting
  • Rezolute Investigative Site, Plano, TexasRecruiting
  • Rezolute Investigative Site, San Antonio, TexasRecruiting
  • Rezolute Investigative Site, The Woodlands, TexasRecruiting
  • Rezolute Investigative Site, Willow Park, TexasRecruiting
  • Rezolute Investigative Site, Lynchburg, VirginiaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

Group 1 - 50 mg RZ402

Group 2 - 200 mg RZ402

Group 3 - 400 mg RZ402

Group 4 - Placebo

Arm Description

Outcomes

Primary Outcome Measures

Safety Events
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Change in Central Subfield Thickness
Change from baseline in Central Subfield Thickness (CST), as measured by Spectral Domain Ocular Coherence Tomography (SD-OCT), compared to placebo.

Secondary Outcome Measures

Change in BCVA
Change from baseline in Best Corrected Visual Acuity (BCVA) in the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score, compared to placebo.
Change from baseline in Diabetic Retinopathy Severity Score (DRSS), compared to placebo.
DRSS is scored on a range from 10 to 90 and where higher scores indicate a worse outcome.
Repeat-dose Cmax of RZ402
Repeat-dose Cmax of RZ402
Repeat-dose T1/2 of RZ402
Repeat-dose T1/2 of RZ402
Repeat-dose AUC of RZ402
Repeat-dose AUC of RZ402

Full Information

First Posted
January 17, 2023
Last Updated
March 29, 2023
Sponsor
Rezolute
search

1. Study Identification

Unique Protocol Identification Number
NCT05712720
Brief Title
Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)
Official Title
A Randomized, Double-Masked, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ402 in Participants With Diabetic Macular Edema (DME)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 6, 2023 (Actual)
Primary Completion Date
September 2023 (Anticipated)
Study Completion Date
January 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rezolute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this trial is to assess the safety, efficacy, and tolerability of RZ402 in patients with Diabetic Macular Edema.
Detailed Description
Diabetic macular edema (DME) is a common retinal microvascular complication in diabetic patients that can lead to progressive loss of visual acuity and ultimately to complete vision loss. DME is the main cause of vision loss in patients with Type 2 diabetes. There is a significant unmet medical need to develop better therapies of DME and diabetic retinopathy (DR). RZ402 is a potent and selective plasma kallikrein inhibitor (PKI), which is being developed as an oral therapy for the chronic treatment of DME and DR. This is a Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ402 in Participants with Diabetic Macular Edema (DME). A screening period of up to 4 weeks will evaluate eligibility. Once enrolled, patients will be randomized with a 1:1:1:1 ratio to receive RZ402 or placebo for up to 12 weeks. After completing dosing, the patient will enter into a 4 week follow up period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Macular Edema
Keywords
Diabetic Macular Edema, Diabetic Retinopathy, Diabetes, Retinal, Macular Thickening, Plasma Kallikrein Inhibitor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group 1 - 50 mg RZ402
Arm Type
Experimental
Arm Title
Group 2 - 200 mg RZ402
Arm Type
Experimental
Arm Title
Group 3 - 400 mg RZ402
Arm Type
Experimental
Arm Title
Group 4 - Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Experimental: Group 1
Intervention Description
RZ402 50 mg oral tablet, once daily for 3 months
Intervention Type
Drug
Intervention Name(s)
Experimental: Group 2
Intervention Description
RZ402 200mg oral tablet, once daily for 3 months
Intervention Type
Drug
Intervention Name(s)
Experimental: Group 3
Intervention Description
RZ402 400mg oral tablet, once daily for 3 months
Intervention Type
Other
Intervention Name(s)
Placebo: Group 4
Intervention Description
Placebo, once daily for 3 months
Primary Outcome Measure Information:
Title
Safety Events
Description
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame
16 weeks
Title
Change in Central Subfield Thickness
Description
Change from baseline in Central Subfield Thickness (CST), as measured by Spectral Domain Ocular Coherence Tomography (SD-OCT), compared to placebo.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Change in BCVA
Description
Change from baseline in Best Corrected Visual Acuity (BCVA) in the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score, compared to placebo.
Time Frame
12 weeks
Title
Change from baseline in Diabetic Retinopathy Severity Score (DRSS), compared to placebo.
Description
DRSS is scored on a range from 10 to 90 and where higher scores indicate a worse outcome.
Time Frame
12 weeks
Title
Repeat-dose Cmax of RZ402
Description
Repeat-dose Cmax of RZ402
Time Frame
16 weeks
Title
Repeat-dose T1/2 of RZ402
Description
Repeat-dose T1/2 of RZ402
Time Frame
16 weeks
Title
Repeat-dose AUC of RZ402
Description
Repeat-dose AUC of RZ402
Time Frame
16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: General Inclusion Criteria: Confirmed diabetes mellitus Type 1 or Type 2 Stable glycemic control Study Eye Inclusion Criteria: Mild to moderate non-proliferative diabetic retinopathy (NPDR) with retinal thickening due to CI-DME as determined by the Investigator. Spectral Domain Optical Coherence Tomography (SD-OCT) foveal CST at screening measuring ≥320 µm (or corresponding values) Best Corrected Visual Acuity ETDRS letter score at 4 meters of ≤78 letters at screening. Media clarity, pupillary dilation, and participant cooperation sufficient for adequate clinical evaluations, OCT images and fundus photographs, at screening. Fellow Eye Inclusion Criteria: Best Corrected Visual Acuity ETDRS letter score at 4 meters of ≥5 letters at screening. Exclusion Criteria: Study Eye Exclusion Criteria: Received more than 3 anti-VEGF injections (including Avastin) and/or received a recent anti-VEGF injection within 8 weeks of Randomization. Any history of retinal surgery or other surgical intervention for DME. Intraocular surgery (including cataract surgery), within 12 weeks prior to Randomization, or anticipated need for ocular surgery during the study period. History of trabeculectomy or other filtration surgery (prior laser trabeculoplasty and placement of iStent®1 in conjunction with cataract surgery is permitted if the procedure took place ≥12 weeks prior to Randomization). Autoimmune idiopathic inflammatory eye disease such as anterior uveitis, or participants with history or signs of chronic inflammation. Full thickness macular hole or retinal detachment. Panretinal, macular focal, or grid laser photocoagulation within 16 weeks of Randomization or anticipated need for the use of laser photocoagulation during the study period. Uncontrolled glaucoma, at screening, defined as IOP ≥25 mmHg. The use of corticosteroids as follows: Topical corticosteroids within 12 weeks prior to Randomization and throughout the remainder of the study. Use of intraocular or sub-Tenon's steroids within 2 years of Randomization in phakic eyes or 9 months of Randomization in pseudophakic eyes, and throughout the remainder of the study. Fellow Eye Exclusion Criteria: Intraocular or sub-Tenon's steroid injection within 6 months of Randomization and throughout the remainder or the study. General Exclusion: Use of the following medications or substances within the specified timeframes below and throughout the remainder of the study. a. Within 16 weeks of Randomization: i. Systemic anti-VEGF or pro-VEGF treatments ii. Systemic, approved, or off-label drugs or devices used to treat DME iii. Participated in an investigational drug or device study within 16 weeks or 5 half-lives (whichever is longer) of Randomization, including systemic or ocular studies iv. Initiation of drugs or substances known to improve or worsen macular edema e.g., Latanoprost or phosphodiesterase-5 (PDE-5) inhibitors (e.g., Sildenafil or others in PDE-5 class), but participants may remain on these drugs if they were initiated >16 weeks prior to Randomization. b. Within 12 weeks of Randomization: i. Use of tobacco- or nicotine- containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, vaping). c. Within 4 weeks of Randomization: i. Anti-coagulants, except for aspirin ≤325 mg/day and/or clopidogrel ≤75 mg/day (or equivalent drug class) ii. Total daily doses of Metformin >1000 mg iii. Total daily doses of niacin (Vitamin B3) >1.5 g/day iv. Use of systemic steroids at supraphysiologic doses (e.g., prednisone equivalent of 5 mg/day or hydrocortisone equivalent of 20 mg/day). v. Drugs that may affect the retina or optic nerve such as quinolones, thioridazine, deferoxamine, ethambutol, vigabatrin, and pentosan. Alanine aminotransferase (ALT), or aspartate aminotransferase (AST), or alkaline phosphatase (ALP) ≥2X upper limit of normal (ULN), total bilirubin ≥1.5X ULN, or gamma-glutamyl transferase (GGT) ≥3X ULN as per the central laboratory. Estimated glomerular filtration rate (eGFR) at ≤45 mL/min and/or history of persistent micro or macro albuminuria. History of current or prior (within 1 year of Randomization) any significant illness, or any medical history History of bariatric surgery or other surgical or medical history History of current or prior (within 1 year of Randomization) abnormal, clinically significant ECG including inadequately controlled hypertension History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding. Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury Known history of human immune-deficiency virus (HIV), hepatitis C, or hepatitis B infection. Malignancies within 3 years prior to Randomization Donated more than 500 mL of blood or significant blood loss within 60 days before Randomization.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Holly Chen
Phone
650-206-4507
Email
RZ402clinicaltrials@rezolutebio.com
First Name & Middle Initial & Last Name or Official Title & Degree
Rajat Agrawal, MD, MS
Phone
650-206-4507
Email
RZ402clinicaltrials@rezolutebio.com
Facility Information:
Facility Name
Rezolute Investigative Site, Phoenix, Arizona
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85020-5505
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Beverly Hills, California
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90211-1841
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Fullerton, California
City
Fullerton
State/Province
California
ZIP/Postal Code
92835-3432
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Modesto, California
City
Modesto
State/Province
California
ZIP/Postal Code
95356-9412
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Santa Barbara, California
City
Santa Barbara
State/Province
California
ZIP/Postal Code
93105
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Coral Springs, Florida
City
Coral Springs
State/Province
Florida
ZIP/Postal Code
33067-3173
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Winter Haven, Florida
City
Winter Haven
State/Province
Florida
ZIP/Postal Code
33880-3919
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Augusta, Georgia
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30909-6440
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Oak Forest, Illinois
City
Oak Forest
State/Province
Illinois
ZIP/Postal Code
60452-2780
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Hagerstown, Maryland
City
Hagerstown
State/Province
Maryland
ZIP/Postal Code
21740-5940
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Rezolute Investigative Site, Royal Oak, Michigan
City
Royal Oak
State/Province
Michigan
ZIP/Postal Code
48073-6710
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Rezolute Investigative Site, Saint Louis Park, Minnesota
City
Saint Louis Park
State/Province
Minnesota
ZIP/Postal Code
55416-5538
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Saint Louis, Missouri
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63128-1729
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Reno, Nevada
City
Reno
State/Province
Nevada
ZIP/Postal Code
89502-1605
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Rezolute Investigative Site, Bloomfield, New Jersey
City
Bloomfield
State/Province
New Jersey
ZIP/Postal Code
07003-3061
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Rezolute Investigative Site, Great Neck, New York
City
Great Neck
State/Province
New York
ZIP/Postal Code
11021-5200
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, New York, New York
City
New York
State/Province
New York
ZIP/Postal Code
10022-2793
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Rezolute Investigative Site, Springfield, Oregon
City
Springfield
State/Province
Oregon
ZIP/Postal Code
97477-1025
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Ladson, South Carolina
City
Ladson
State/Province
South Carolina
ZIP/Postal Code
29456-4118
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Austin, TX
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Bellaire, Texas
City
Bellaire
State/Province
Texas
ZIP/Postal Code
77401
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, McAllen, Texas
City
McAllen
State/Province
Texas
ZIP/Postal Code
78503-1518
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Plano, Texas
City
Plano
State/Province
Texas
ZIP/Postal Code
75075-5025
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, San Antonio, Texas
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78240-1502
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, The Woodlands, Texas
City
The Woodlands
State/Province
Texas
ZIP/Postal Code
77384-4167
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Willow Park, Texas
City
Willow Park
State/Province
Texas
ZIP/Postal Code
76087-9133
Country
United States
Individual Site Status
Recruiting
Facility Name
Rezolute Investigative Site, Lynchburg, Virginia
City
Lynchburg
State/Province
Virginia
ZIP/Postal Code
24502-4271
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)

We'll reach out to this number within 24 hrs